Literature DB >> 10443662

Antimüllerian hormone in patients with hypogonadotropic hypogonadism.

J Young1, R Rey, B Couzinet, P Chanson, N Josso, G Schaison.   

Abstract

Antimullerian hormone (AMH) is produced by immature Sertoli cells until pubertal maturation. At puberty, elevation of serum testosterone correlates with a decrease in serum AMH. To further investigate the hormonal control of AMH secretion, serum AMH levels were measured in 20 normal men (20-60 yr), in 12 patients (19-30 yr) with congenital hypogonadotropic hypogonadism (CHH), and in 18 patients (19-65 yr) with acquired hypogonadotropic hypogonadism (AHH) either untreated or during testosterone or human chorionic gonadotropin (hCG) therapy. Mean serum AMH levels in normal adult men were low (20+/-4.9 pmol/L). In untreated CHH patients, mean serum AMH levels were significantly higher than in normal men (292+/-86 pmol/L, P < 0.001) and were similar to those previously reported in prepubertal boys. In men with AHH, mean serum AMH levels were also significantly increased (107+/-50 pmol/L; P < 0.01) when compared with healthy men but were less than in men with CHH. In addition, in 10 patients treated for prostate cancer, a modest but significant increase of serum AMH (from 11.4 +/-5.7 pmol/L to 49+/-9.9 pmol/L; P < 0.01) was observed 12 months after suppression of the gonadal axis with the GnRH agonist Triptorelin (3.75 mg IM once a month). Plasma testosterone (T) and serum AMH levels were measured at baseline and at 3 and 6 months in 10 HH patients (6 CHH and 4 AHH) treated with hCG (1500 IU/twice weekly for 6 months) and in 8 HH (4 CHH and 4 AHH) patients treated with T (T enanthate 250 mg/3 weeks for 6 months). hCG treatment induced an increase of plasma T (from 1.0+/-0.7 to 11+/-2.4 and 19+/-4.8 nmol/L, at 3 and 6 months respectively) associated with a dramatic decrease of serum AMH (from 314+/-93 to 56+/-30 and 17+/-4.3 pmol/L). The similar increase in plasma T levels (from 1.4+/-1.0 to 15.6+/-4.2 and 23+/-6.2 ng/mL) obtained with exogenous T induced a lesser decrease of serum AMH (from 221+/-107 pmol/L to 114+/-50 and 66+/-17 pmol/L, at 3 and 6 months respectively). In conclusion, high plasma AMH levels in CHH patients are related to the absence of pubertal maturation of Sertoli cells. The high AMH levels in AHH and its increase after Triptorelin-induced gonadotropin deficiency suggest that the suppression of AMH is a reversible phenomenon. Finally, the inhibition of AMH production by Sertoli cells is induced by intratesticular T.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10443662     DOI: 10.1210/jcem.84.8.5972

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  19 in total

1.  Serum Anti-Müllerian Hormone in the Prediction of Response to hCG Stimulation in Children With DSD.

Authors:  Angela K Lucas-Herald; Andreas Kyriakou; Malika Alimussina; Guilherme Guaragna-Filho; Louise A Diver; Ruth McGowan; Karen Smith; Jane D McNeilly; S Faisal Ahmed
Journal:  J Clin Endocrinol Metab       Date:  2020-05-01       Impact factor: 5.958

Review 2.  Evaluation of testicular function in prepubertal children.

Authors:  Rosita A Condorelli; Rossella Cannarella; Aldo E Calogero; Sandro La Vignera
Journal:  Endocrine       Date:  2018-07-07       Impact factor: 3.633

Review 3.  Expert consensus document: European Consensus Statement on congenital hypogonadotropic hypogonadism--pathogenesis, diagnosis and treatment.

Authors:  Ulrich Boehm; Pierre-Marc Bouloux; Mehul T Dattani; Nicolas de Roux; Catherine Dodé; Leo Dunkel; Andrew A Dwyer; Paolo Giacobini; Jean-Pierre Hardelin; Anders Juul; Mohamad Maghnie; Nelly Pitteloud; Vincent Prevot; Taneli Raivio; Manuel Tena-Sempere; Richard Quinton; Jacques Young
Journal:  Nat Rev Endocrinol       Date:  2015-07-21       Impact factor: 43.330

Review 4.  Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine.

Authors:  Vitaly A Kushnir; David B Seifer; David H Barad; Aritro Sen; Norbert Gleicher
Journal:  J Assist Reprod Genet       Date:  2017-06-22       Impact factor: 3.412

5.  Lack of androgen receptor expression in Sertoli cells accounts for the absence of anti-Mullerian hormone repression during early human testis development.

Authors:  Kahina Boukari; Geri Meduri; Sylvie Brailly-Tabard; Jean Guibourdenche; Maria Luisa Ciampi; Nathalie Massin; Laetitia Martinerie; Jean-Yves Picard; Rodolfo Rey; Marc Lombès; Jacques Young
Journal:  J Clin Endocrinol Metab       Date:  2009-03-10       Impact factor: 5.958

6.  The impact of depot GnRH agonist on AMH levels in healthy reproductive-aged women.

Authors:  H Irene Su; Kevin Maas; Patrick M Sluss; R Jeffrey Chang; Janet E Hall; Hadine Joffe
Journal:  J Clin Endocrinol Metab       Date:  2013-09-30       Impact factor: 5.958

7.  The Daily Profiles of Circulating AMH and INSL3 in Men are Distinct from the Other Testicular Hormones, Inhibin B and Testosterone.

Authors:  Yih Harng Chong; Michael W Pankhurst; Ian S McLennan
Journal:  PLoS One       Date:  2015-07-20       Impact factor: 3.240

8.  Congenital hypogonadotropic hypogonadism during childhood: presentation and genetic analyses in 46 boys.

Authors:  Audrey Vizeneux; Aude Hilfiger; Jérôme Bouligand; Monique Pouillot; Sylvie Brailly-Tabard; Anu Bashamboo; Ken McElreavey; Raja Brauner
Journal:  PLoS One       Date:  2013-10-24       Impact factor: 3.240

9.  Prior testosterone replacement therapy may impact spermatogenic response to combined gonadotropin therapy in severe congenital hypogonadotropic hypogonadism.

Authors:  Ravikumar Shah; Virendra Patil; Vijaya Sarathi; Anurag R Lila; Margaret Zacharin; Brijesh Krishnappa; Manjeetkaur Sehemby; Sanjeet Kumar Jaiswal; Pratap L Jadhav; Swati Ramteke-Jadhav; Nalini Shah; Tushar Bandgar
Journal:  Pituitary       Date:  2020-11-23       Impact factor: 4.107

Review 10.  Anti-müllerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development.

Authors:  Marie Lindhardt Johansen; Casper P Hagen; Trine Holm Johannsen; Katharina M Main; Jean-Yves Picard; Anne Jørgensen; Ewa Rajpert-De Meyts; Anders Juul
Journal:  Int J Endocrinol       Date:  2013-12-03       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.